Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Entrada Therapeutics
company
About
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
- Boston,Massachusetts,United States
- 51 - 100
- https://www.entradatx.com
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $26M
- Industries
- Biotechnology,Emergency Medicine,Genetics,Health Care,Medical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:TRDA
- Legal Name
- Entrada Therapeutics, Inc.
- Also Known As
- Entrada
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$383.09M
Entrada Therapeutics has raised a total of
$383.09M
in funding over 2 rounds. Their latest funding was raised on
Dec 8, 2022 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 8, 2022 | Series Unknown | $26M | — | — | — | Detail |
| Oct 29, 2021 | IPO | $181.50M | — | — | — | Detail |
| Mar 31, 2021 | Series B | $116M | 14 |
Wellington Management
|
— | Detail |
| Dec 18, 2018 | Series A | $59M | 5 |
5AM Ventures
|
— | Detail |
| Oct 27, 2016 | Seed | $599.99K | — | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
3
14
Entrada Therapeutics is funded by 14 investors.
Wellington Management
and 5AM Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Wellington Management
|
Yes | Series B |
|
5AM Ventures
|
— | Series B |
Agent Capital
|
— | Series B |
CureDuchenne Ventures
|
— | Series B |
Goldman Sachs
|
— | Series B |
Greenspring Associates
|
— | Series B |
|
|
— | Series B |
|
|
— | Series B |
MRL Ventures Fund
|
— | Series B |
Point72 Ventures
|
— | Series B |
Employee Profiles
Number of Employee Profiles
7
Entrada Therapeutics has 7 current employee profiles, including
Board member Kush Parmar
Board member
Executive
Executive
Executive
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
